Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

Stephen M. Ansell, MD, PhD
Published: Thursday, Jun 22, 2017



Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.
SELECTED
LANGUAGE


Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x